EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme

Pierre-Régis Burgel iD

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00233-2024 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Pierre-Régis Burgel. Beteiligte Einrichtung: Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France pierre-regis.burgel@aphp.fr. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Indoles, Aminophenols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Filière Maladies Rares MUCO-CFTR, Société Française de la Mucoviscidose, Association Vaincre la Mucoviscidose.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shareable abstract Lists of CFTR variants responsive and non-responsive to elexacaftor/tezacaftor/ivacaftor will help in expanding eligibility for people with cystic fibrosis carrying rare CFTR variantshttps://bit.ly/3HQioXl

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesIndolesAminophenolsPyrazolesPyridinesPyrrolidinesQuinolonesHumansCompassionate Use TrialsCystic Fibrosis Transmembrane Conductance Regulator

Substanzen

elexacaftorivacaftortezacaftorCystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, humanBenzodioxolesIndolesAminophenolsPyrazolesPyridines

Autor:innen und Institutionen

  • Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France pierre-regis.burgel@aphp.fr.
  • Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France.

ORCID-Profile: Pierre-Régis Burgel

Förderung

  • Filière Maladies Rares MUCO-CFTR
  • Société Française de la Mucoviscidose
  • Association Vaincre la Mucoviscidose

Zitieren

APA

Burgel, P. R. (2024). Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. European Respiratory Journal. https://doi.org/10.1183/13993003.00233-2024

Vancouver

Burgel PR. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. European Respiratory Journal. 2024. doi:10.1183/13993003.00233-2024

BibTeX
@article{Burgel2024,
  author = {Burgel, Pierre-Régis},
  title = {Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00233-2024}
}
Kostenlos starten →